Sign inJoin waitlistJoin the waitlist

Joshua Sabari

Director, High Reliability Organization Initiatives, Perlmutter Cancer Center · NYU Grossman School of Medicine

Credentials: · ·

History

NYU Grossman School of Medicine
Present
NYU Grossman Long Island School of Medicine · NYU Grossman School of Medicine
Present

Memorial Sloan Kettering Cancer Center
2016–2018
Montefiore Einstein
2012–2015
Rutgers University
2007–2011

Research

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Annals of Oncology · 2019 · 1,133 citations
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
New England Journal of Medicine · 2022 · 871 citations
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Journal of Clinical Oncology · 2018 · 870 citations

AD
Alexander Drilon
13 papers
AS
Alexander Spira
11 papers
Charles Rudin
10 papers
Rachel Sanborn
10 papers
ML
Marc Ladanyi
9 papers
GR
Gregory Riely
8 papers
Elaine Shum
7 papers
MA
Maria Arcila
7 papers
MK
Mark Kris
7 papers
NR
Natasha Rekhtman
7 papers
RK
Roland Knoblauch
7 papers
BL
Bob Li
6 papers

Clinical trials

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
Principal investigator · Terminated · Phase 2
NYU Langone Health
2017–2019
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2023–2031